The Role of Adaptive Immune Response in Alzheimer’s Disease: Focus on Amyloid Beta-Reactive T Cells and Amyloid Beta-Specific Antibodies
Open Access
- 21 August 2026
- journal article
- Published by LIDSEN Publishing Inc in OBM Neurobiology
- Vol. 010 (03) , 1-13
Abstract
Alzheimer’s disease is one of the most prevalent neurodegenerative diseases among older people. Generally, there are two main pathologies of Alzheimer’s disease, including the accumulation of amyloid beta and the hyperphosphorylation of the microtubule-associated Tau protein in the brain. Recently, more studies have discovered that changes in the immune system can be one of the causes of amyloid-beta deposits. Amyloid-beta is a product of the breakdown of the glycoprotein amyloid precursor protein, a transmembrane protein that is cleaved by β-secretase and γ-secretase. In the brain, amyloid-beta deposits can trigger microglia activation, which helps eliminate the deposits. However, microglia activation may induce neuroinflammation by releasing pro-inflammatory cytokines and damage the blood-brain barrier, which can cause an influx of peripheral immune cells, including the adaptive immune system, into the brain. The role of the adaptive immune system in Alzheimer’s disease pathology is quite complicated and may alter due to aging. Aging can directly alter the immune system by reducing protective immunity through reduced production of naïve T cells and increased memory T cells. The increase in memory T cells, which have already recognized specific antigens, such as amyloid beta, may act as amyloid beta-reactive T cells and induce activation and release of amyloid beta-specific antibodies from B cells. This condition increases neuroinflammatory processes. Several drugs that directly target the immune system showed promising results as Alzheimer’s disease progressed. However, due to limited data, inconsistent results, and late adverse outcome effects, these drugs still require further research.Keywords
This publication has 95 references indexed in Scilit:
- A double-edged sword: Exploring the neuroprotective/damaging mechanisms of complement activation in Alzheimer's diseaseAging and Health Research, 2025
- Aβ‐reactive T cell polyfunctionality response as a new biomarker for mild cognitive impairmentAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2025
- Early β‐amyloid accumulation in the brain is associated with peripheral T cell alterationsAlzheimer's & Dementia, 2023
- Impact of IL-21-associated peripheral and brain crosstalk on the Alzheimer’s disease neuropathologyCellular and Molecular Life Sciences, 2022
- Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker researchAlzheimer's & Dementia, 2021
- Gut Microbiota and Dysbiosis in Alzheimer’s Disease: Implications for Pathogenesis and TreatmentMolecular Neurobiology, 2020
- Targeting of Perforin Inhibitor into the Brain Parenchyma Via a Prodrug Approach Can Decrease Oxidative Stress and Neuroinflammation and Improve Cell SurvivalMolecular Neurobiology, 2020
- The role of the immune system in Alzheimer disease: Etiology and treatmentAgeing Research Reviews, 2017
- Intracranial IL-17A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer’s diseaseBrain, Behavior, and Immunity, 2017
- Cerebral regulatory T cells restrain microglia/macrophage‐mediated inflammatory responses via IL‐10European Journal of Immunology, 2014